# Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

> **NCT02475720** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2000 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02475720
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-19
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-03-16
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475720, "Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02475720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*